budesonide + formoterol + tiotropium

A combination therapy consisting of budesonide (an inhaled corticosteroid), formoterol (a long-acting β2-agonist), and tiotropium bromide (a long-acting muscarinic antagonist). This triple therapy is used for treating respiratory conditions, particularly chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap syndrome (ACOS). This combination therapy brings together three different mechanisms of action to provide enhanced bronchodilation, anti-inflammatory effects, and improved pulmonary function. Budesonide is an anti-inflammatory glucocorticoid that inhibits airway inflammation, prevents airway remodeling, and increases the number of cell membrane β2 receptors[5]. Formoterol is a highly selective long-acting β2 receptor agonist that improves airway obstruction and pulmonary function, providing immediate bronchodilation and symptomatic relief[5][7]. Tiotropium bromide is a long-acting muscarinic antagonist (LAMA) that provides additional bronchodilation through a different mechanism than formoterol[5][7]. The three medications work synergistically - tiotropium and formoterol further increase the bronchodilatory effect through different mechanisms, while budesonide addresses the underlying inflammation[5]. This combination is particularly beneficial during exacerbations, effectively providing a temporary step-up in therapy[7]. Multiple studies have demonstrated that this triple combination therapy significantly improves pulmonary function parameters, exercise capacity (6-minute walk test), quality of life scores, morning symptoms and activities, endothelial function, immune status, and reduces severe exacerbations (by up to 62%). The therapy is generally well-tolerated, with potential adverse effects including Candida infection, dry mouth, constipation, palpitation, and dysuria. Some studies reported lower adverse reaction rates compared to conventional therapy.